Selected article for: "complement activation and direct neutralization"
Author: Rojas, Manuel; Rodríguez, Yhojan; Monsalve, Diana M.; Acosta-Ampudia, Yeny; Camacho, Bernardo; Gallo, Juan Esteban; Rojas-Villarraga, Adriana; Ramírez-Santana, Carolina; Díaz-Coronado, Juan C.; Manrique, Rubén; Mantilla, Ruben D.; Shoenfeld, Yehuda; Anaya, Juan-Manuel
Title: Convalescent plasma in Covid-19: Possible mechanisms of action
  • Cord-id: ha5nszxi
  • Document date: 2020_5_5
    • ID: ha5nszxi
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the po
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.

    Search related documents:
    Co phrase search for related documents
    • active infection and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • active infection and acute viral infection: 1, 2, 3, 4, 5
    • active infection and adaptive immunity: 1, 2, 3
    • active infection and additional study: 1
    • active infection and lopinavir ritonavir: 1, 2
    • active infection and lung damage: 1, 2, 3, 4, 5, 6
    • active infection and lung inflammation: 1, 2, 3, 4, 5
    • active infection and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active infection and lupus erythematosus: 1, 2, 3
    • active infection and lymphocyte count: 1, 2, 3
    • active infection and macrophage activation: 1, 2
    • active infection patient and acute respiratory syndrome: 1, 2, 3, 4, 5
    • active infection patient and lung damage: 1
    • acute rejection and adaptive immunity: 1, 2
    • acute rejection and lung damage: 1, 2
    • acute rejection and lung inflammation: 1, 2, 3